Tempest Therapeutics, Inc. (TPST)
NASDAQ: TPST · Real-Time Price · USD
0.860
-0.047 (-5.14%)
At close: Feb 21, 2025, 4:00 PM
0.910
+0.049 (5.75%)
After-hours: Feb 21, 2025, 7:57 PM EST
Tempest Therapeutics Employees
Tempest Therapeutics had 17 employees as of December 31, 2023. The number of employees decreased by 2 or -10.53% compared to the previous year.
Employees
17
Change (1Y)
-2
Growth (1Y)
-10.53%
Revenue / Employee
n/a
Profits / Employee
-$2,089,294
Market Cap
37.55M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 17 | -2 | -10.53% |
Dec 31, 2022 | 19 | 2 | 11.76% |
Dec 31, 2021 | 17 | 3 | 21.43% |
Dec 31, 2020 | 14 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
TPST News
- 12 days ago - Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma - GlobeNewsWire
- 15 days ago - Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC) - GlobeNewsWire
- 3 months ago - Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 3 months ago - Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday? - Benzinga
- 4 months ago - Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial - GlobeNewsWire
- 5 months ago - Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire